NCT07288619Completed
Therapeutic Efficacy of Nutritional Supplementation in Cachexia Associated With Chronic Pulmonary Disease
Evaluation of the Clinical Effectiveness of Nutritional Supplements in Pulmonary Cachexia: A Quasi-Experimental Trial of n-3 PUFAs and Vitamin D
Source: ClinicalTrials.gov · Last updated 4 Jun 2026
Brief summary (registry, in English)
Pulmonary cachexia, observed in individuals with chronic obstructive pulmonary disease (COPD) is a multifactorial syndrome characterized by disruptions in energy metabolism, increased protein degradation, and an impaired capacity to preserve muscle mass. These metabolic disturbances not only exacerbate the underlying respiratory condition but also significantly contribute to elevated mortality rates among affected individuals. Current therapeutic strategies for managing cachexia primarily emphasize pharmacological treatments, nutritional interventions, and multimodal approaches. Among the nutritional interventions, various supplements have shown potential in mitigating the catabolic processes associated with cachexia. Notably, supplementation with n-3 polyunsaturated fatty acids (n-3 PUFAs) and vitamin D has emerged as a promising intervention, likely due to their involvement in key pathological mechanisms underlying the disease. While previous studies have investigated the combined effects of these supplements through oral nutritional supplementation, this study aims to evaluate and compare the clinical effectiveness of n-3 PUFAs and vitamin D as distinct therapeutic interventions for managing pulmonary cachexia.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 45 (actual)
- First submitted
- 20 Nov 2025
- Start date
- 15 Oct 2025
- Primary completion date
- 15 Mar 2026
- Lead sponsor
- Safeer Khan
- Diseases
- COPD
- NCT number
- NCT07288619
What you commit to
- Study type: Interventional
- Participants enrolled: 45
- From 15 Oct 2025 to the primary completion date, 15 Mar 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients on oral or parenteral corticosteroids for more than four weeks.
Other illness
- Patients with co-morbid chronic diseases that can also cause cachexia, including cancer, HIV/AIDS, heart failure, chronic renal failure, liver cirrhosis, and rheumatoid arthritis
- Patients with a history of allergies to fish-derived products, n-3 polyunsaturated fatty acids (PUFAs), or Vitamin D.
- Patients with a metabolic disorder that can lead to changes in body composition.
Other
- Patients experiencing acute exacerbations of COPD.
- Pregnant women and patients with abnormal liver and/or renal function tests.
- Patients who have taken n-3 PUFAs, Vitamin D, or any intervention for cachexia in the past four weeks.
Who the study is looking for
- Able to provide both written and verbal consent.
- Clinically diagnosed with chronic obstructive pulmonary disease (COPD).
- Diagnosis of pulmonary cachexia according to Cachexia Consensus Conference criteria
Age in the registry: 18 years to 55 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Gulab Devi Teaching Hospital, Lahore Coordinator of this site? Confirm its status | Lahore | Pakistan | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.